Literature DB >> 16697005

Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice.

K F J de Brouwer1, H Degens, W M Aartsen, M Lindhout, N J J E Bitsch, A J Gilde, P H M Willemsen, B J A Janssen, G J van der Vusse, M van Bilsen.   

Abstract

Preferential and specific down-regulation of genes involved in fatty acid (FA) uptake and metabolism is considered a hallmark of severe hypertrophic remodeling and progression to cardiac failure. Therefore, we investigated the time course of changes in cardiac metabolic gene expression (1) in mice subjected to regional myocardial infarction (MI) for 4 days, 1 month, or 3 months and (2) in mice overexpressing calcineurin (Cn) which initially develop concentric hypertrophy progressing after the age of 4 weeks to dilated cardiomyopathy and failure. In both models, hypertrophy was characterized by increased expression of beta-myosin heavy chain protein and atrial natriuretic factor mRNA, indicative of marked structural remodeling. Fractional shortening progressively decreased from 31% to 15.1% and 3.7% 1 and 3 months after MI, respectively. One month post-MI, the expression of several metabolic genes, i.e., acyl-CoA synthetase (-50%), muscle-type carnitine palmitoyl transferase 1 (-37%) and citrate synthase (-28%), was significantly reduced in the surviving myocardium. Despite overt signs of cardiac failure 3 months post-MI, the expression of these genes had returned to normal levels. In hearts of both 4- and 6-week-old Cn mice, genes involved in both FA and glucose metabolism and mitochondrial citrate synthase were down-regulated, reflecting an overall decline in metabolic gene expression, rather than a specific and preferential down-regulation of genes involved in FA uptake and metabolism. These findings challenge the concept that specific and sustained down-regulation of genes involved in FA uptake and metabolism represents a hallmark of the development of cardiac hypertrophy and progression to failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697005     DOI: 10.1016/j.yjmcc.2006.03.429

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

Review 1.  Energetics and metabolism in the failing heart: important but poorly understood.

Authors:  Aslan T Turer; Craig R Malloy; Christopher B Newgard; Mihai V Podgoreanu
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

Review 2.  A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.

Authors:  Ashish Gupta; Brian Houston
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 3.  Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.

Authors:  Yan Burelle; Maya Khairallah; Alexis Ascah; Bruce G Allen; Christian F Deschepper; Basil J Petrof; Christine Des Rosiers
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

Review 4.  Alterations in mitochondrial function in cardiac hypertrophy and heart failure.

Authors:  Moritz Osterholt; T Dung Nguyen; Michael Schwarzer; Torsten Doenst
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

5.  Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.

Authors:  Brian D Lowes; Ronald Zolty; Simon F Shakar; Andreas Brieke; Norman Gray; Michael Reed; Mihail Calalb; Wayne Minobe; JoAnn Lindenfeld; Eugene E Wolfel; Mark Geraci; Michael R Bristow; Joseph Cleveland
Journal:  J Heart Lung Transplant       Date:  2007-11       Impact factor: 10.247

6.  Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload.

Authors:  David J Chess; Biao Lei; Brian D Hoit; Agnes M Azimzadeh; William C Stanley
Journal:  J Card Fail       Date:  2008-02       Impact factor: 5.712

7.  Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling.

Authors:  Frans A van Nieuwenhoven; Chantal Munts; Roel C Op't Veld; Arantxa González; Javier Díez; Stephane Heymans; Blanche Schroen; Marc van Bilsen
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.